Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · IEX Real-Time Price · USD
7.11
-0.11 (-1.52%)
At close: Jul 19, 2024, 4:00 PM
7.20
+0.09 (1.27%)
Pre-market: Jul 22, 2024, 8:17 AM EDT
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 49 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
49
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,653
Profits / Employee
-$947,980
Market Cap
211.76M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Inogen | 834 |
The Joint | 794 |
23andMe Holding Co. | 582 |
Butterfly Network | 225 |
Molecular Partners AG | 168 |
Century Therapeutics | 165 |
Caribou Biosciences | 158 |
Shattuck Labs | 75 |
ATNM News
- 5 weeks ago - Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML) - Newsfile Corp
- 5 weeks ago - Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress - PRNewsWire
- 5 weeks ago - Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial - PRNewsWire
- 5 weeks ago - Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting - PRNewsWire
- 6 weeks ago - Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting - PRNewsWire
- 2 months ago - Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity - PRNewsWire
- 2 months ago - Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Pha - PRNewsWire
- 2 months ago - Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting - PRNewsWire